With the Own It effort, Medtronic is providing a way for those living with diabetes to celebrate ordinary moments made possible with the right technology so they can own every choice.

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures DUBLIN and FLORENCE, Italy, March 9, 2024 ...

The first study by Dr. Goran Petrovski, MD, PhD, of Sidra Medicine, randomly assigned adolescents using the MiniMed™ 780G system (n=34) into two groups, with some entering a fixed pre-set number of ...

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn ...

GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...

DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...

Medtronic plc MDT announced one-year data from the ADAPT study -- the first multi-national randomized controlled study evaluating the performance of the MiniMed 780G advanced hybrid closed loop ...

MiniMed has filed IPO registration with SEC as Medtronic moves forward with the spin off of its diabetes division.